4 reasons to switch from formoterol to salmeterol Review article
Article Sidebar
Published:
Nov 30, 2023
Keywords:
asthma, chronic obstructive pulmonary disease, treatment, salmeterol, safety
Main Article Content
Abstract
Asthma and chronic obstructive pulmonary disease are among the most common conditions in the GP’s office. These are diseases that significantly impair the quality of life of patients. These diseases require intensive, effective and chronic treatment, and patients need constant care. Each patient should be approached individually and the safety and effectiveness of treatment should always be assessed. The presented arguments indicate that it is sometimes worth replacing formoterol with salmeterol.
Article Details
How to Cite
Sybilski , A. J. (2023). 4 reasons to switch from formoterol to salmeterol. Medycyna Faktow (J EBM), 16(3(60), 319-321. https://doi.org/10.24292/01.MF.0323.06
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Global Strategy for Asthma Management and Prevention (2023 update). (dostęp 07.09.2023.)
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report. Global Initiative for Chronic Obstructive Lung Disease; 2023. (dostęp: 07.09.2023).
3. Hoogsteden HC, Verhoeven GT, Lambrecht BN et al. Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigenpresenting dendritic cell: influence of treatment with fluticasone propionate. Clin Exp Allergy. 1999; 29: 116-24.
4. Kowal K. 10 powodów, dzięki którym terapia astmy i przewlekłej obturacyjnej choroby płuc salmeterolem z propionianem flutykazonu w inhalatorze DPI może być bardzo skuteczna i bezpieczna. Alergoprofil. 2023; 19(1): 17-22.
5. Pace E, Gagliardo R, Melis M et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol. 2004; 114: 1216-23.
6. Ferguson GT, Funck-Brentano C, Fischer T et al. Cardiovascular safety of salmeterol in COPD. Chest. 2003; 123(6): 1817-24.
7. Price DB, Williams AE, Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Respir Res. 2007; 8(1): 46.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for prevention, diagnosis and management of COPD: 2023 report. Global Initiative for Chronic Obstructive Lung Disease; 2023. (dostęp: 07.09.2023).
3. Hoogsteden HC, Verhoeven GT, Lambrecht BN et al. Airway inflammation in asthma and chronic obstructive pulmonary disease with special emphasis on the antigenpresenting dendritic cell: influence of treatment with fluticasone propionate. Clin Exp Allergy. 1999; 29: 116-24.
4. Kowal K. 10 powodów, dzięki którym terapia astmy i przewlekłej obturacyjnej choroby płuc salmeterolem z propionianem flutykazonu w inhalatorze DPI może być bardzo skuteczna i bezpieczna. Alergoprofil. 2023; 19(1): 17-22.
5. Pace E, Gagliardo R, Melis M et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol. 2004; 114: 1216-23.
6. Ferguson GT, Funck-Brentano C, Fischer T et al. Cardiovascular safety of salmeterol in COPD. Chest. 2003; 123(6): 1817-24.
7. Price DB, Williams AE, Yoxall S. Salmeterol/fluticasone stable-dose treatment compared with formoterol/budesonide adjustable maintenance dosing: impact on health-related quality of life. Respir Res. 2007; 8(1): 46.